31 results about "Primaquine" patented technology

The invention relates to a preparation method of new preparation of erythrocin, which is characterized in that an endothelin core of erythrocin is prepared, and then an isolating layer, a protective layer, a second isolating layer and an improved enteric-coating material layer are applied one by one. In this way, new preparation of the erythrocin which has certain feature of releasing (dissolving) in acid solution (hydrochloric acid solution 9 to 1000) can be formed. The technology of the new preparation can also be widely applied to drugs which, like erythrocin, when being taken orally by a patient, cause the patient to suffer the side effects of stimulation, sickness and the like after degradation in the stomach of the patient or contact with the stomach of the patient, and drugs which the patient needs to take orally to let the blood concentration to reach the peak value in a short time. Such drugs include macrolides of azithromycin, metronidazole of nitroimidazoles, tinidazole, acyclovir as an antiviral drug, ammonium chloride as a phlegm eliminating drug, bromhexine, chloroquine as an antimalarial, nitroquine, artemisinin, dihydroartemisinin, artesunate, primaquine, pyrimethamine, carbarsone and emetine amebicides and so on.

The invention belongs to the field of membrane separation and particularly relates to a polysulfone side chain grafted polymerized tertiary amine micro-filtration membrane. The problems that in the prior art, the reject rate on many micromolecular substances is low, consequently, removal of poisonous substances cannot reach the standard, and the operation cost of the nanofiltration technology is high can be solved. According to a preparation method, a phase conversion film forming method is firstly adopted for preparing a chloromethyl polysulfone (CMPSF) asymmetric micro-filtration membrane; then primaquine groups are introduced to the surface of the micro-filtration membrane through surface chemical modification; finally, on the basis of constructing a -NH2/S2O82-surface initiating system, tertiary amine monomer dimethyl amino ethyl methacrylate (DMAEMA) is grafted and polymerized on the surface of the membrane, and the porous grafted membrane PSF-g-PDMAEMA grafted with functional macromolecular PDMAEMA is prepared. The prepared polysulfone side chain grafted polymerized tertiary amine micro-filtration membrane can efficiently remove two kinds of poisonous anions such as CrO42- and MoO42-.

The invention discloses a synthesis method of a half-antigen and a complete antigen of tulathromycin and belongs to the technical field of immunology. The method synthesizes the half-antigen of tulathromycin by carrying out hydroxyl on tulathromycin by a succinic anhydride method and introducing free carboxyl. Derivated free carboxyl reacts with primaquine of bovine serum albumin to form an amido bond for coupling by an active ester method to form the complete antigen of tulathromycin. After the antigens are used for immunizing a Balb/c mouse for three times, the valence can reach 1:8000. The antigens have wide practical application prospects.

This invention discloses an immunosuppressive cell-capturing material comprising a molded body that includes: a readily hydrolyzable condensation polymer having an amino group; a poorly hydrolyzable polymer coating the readily hydrolyzable condensation polymer; and a ligand-conjugated poorly hydrolyzable polymer coating the poorly hydrolyzable polymer, wherein the ligand is at least one selected from the group consisting of a NH₂ group, a secondary amino group, a tertiary amino group, a polyamine residue, a basic cyclic polypeptide residue, an aminoglycosidic compound residue, chloroquine, primaquine, mefloquine, imiquimod, and nystatin, and wherein the content of the amino group in the molded body is 150 μmol/g or less. The invention also discloses an immunosuppressive cell-capturing column filled with the capturing material.

The invention relates to a combination Western-Chinese pharmaceutical slow release injection for treating rabbit coccidiosis and process for preparation, wherein the constituents of the injection include (by weight percent): sweet wormwood 3-6 parts, flavescent sophora root 3-6 parts, Chinese pulsatilla root 2-5 parts, hairy vein agrimony 2-5 parts, bupleurum root 1-3 weight parts, garden burnet root 1-3 parts, astragalus root 1-3 parts, primaquine 0.06-0.35 part, beta-cyclodextrin 2-4 parts. The preparing process consists of drying the raw material herbs, disintegrating, mixing, ethanol extracting, water extracting, removing foreign substance, mixing the extract with primaquine and beta-cyclodextrin, grinding, dressing and adjusting soup volume.

The present invention provides a novel combination comprising artemisinin in the form of tablets and related dosage forms for pediatric use, such as granules, suppository, suspension syrup and dry powder, for the treatment of human malarias including multiple-resistant subtertian malaria, tertian malaria and quartan malaria. Said combination is comprised of artemisinin, piperaquine and primaquine. Clinical tests in Southeast Asia countries where malaria is epidemic demonstrate that, apart from having high and rapid therapeutic effect possessed by the most excellent domestic and foreign artemisinin-type anti-malarial drugs, the present combination is also featured with shorter course of treatment, less side effect, lower material cost, and more convenience for administration, and its ability of rapidly killing gametophyte and cutting off infection source thereby blocking spreading of malaria is a further improvement.

The invention discloses a medicine combination used to cure or prevent malaria, which basically consists of arteannuin or derivatives thereof, naphthoquine and primaquine. The invention can be used in curing malignant malaria, quartan malaria and tertian malaria and is particularly suitable to cure malignant malaria with multi-drug resistance through adopting one dose therapeutics. The invention has good curative effect, less toxic and side effect and low cost, thereby being particularly suitable for fast control and elimination of malaria in various regions.

The invention discloses poloxamer-adriamycin conjugate (DOX-P) micelle with anti-tumor drug resistance and a preparation method of the DOX-P micelle. The synthetic process of the DOX-P comprises the steps of firstly, reacting poloxamer with succinic anhydride to obtain high-molecular polymer of which the tail end contains carboxyl; and then, directly bonding the carboxyl at the tail end of the polymer with primaquine group in the adriamycin in an amido bond mode. The DOX-P has the capability of forming the micelle; and compared with the adriamycin bulk drug, the adriamycin subjected to covalent binding in the DOX-P micelle has the advantages that the anti-tumor activity of the adriamycin is maintained, the drug resistance of the tumor is overcome, and the stability of the adriamycin is better than that of poloxamer micelle.

The invention relates to a colorimetric detection method for primaquine drugs. In an acidic environment and in the presence of nitrite, para substituent-containing aniline can produce a Griess reaction with primaquine to form a colored azo product; a UV-Vis absorption spectrum and a maximum light absorption value of the colored product are determined; formation of the colored azo product and a change of a light absorption value thereof are detected in the presence of the primaquine with different concentrations by a microplate reader; a standard curve of the concentration of the primaquine andthe light absorption value of the azo product is established; and the concentration of the primaquine drugs in a to-be-tested sample is determined by a corresponding relation between the concentration of the primaquine and the light absorption value of the azo product on the standard curve. The method is successfully used for quantitatively analyzing and synthetizing the concentration of the primaquine in urine, and a detection limit is as low as 0.63 [mu]M. The method can also detect the primaquine from a serum sample within a clinically relevant concentration range.

The present invention a novel use of primaquine derivative N¹-(3-ethylidinotetrahydrofuran-2-one)-N⁴-(6-methoxy-8-quinolinyl)-1,4-pentanediamine in the treatment and controlling the spread of malaria. In particular, the present invention discloses a method of treatment of malaria by the use of primaquine derivative N¹-(3-ethylidinotetrahydrofuran-2-one)-N⁴-(6-methoxy-8-quinolinyl)-1,4-pentanediamine as a gametocytocidal agent.

The invention relates to an antimalarial green tea chewing gum which is characterized by being made from the following raw materials by weight portion: 0.1-5 portions of artemisinin, 0.3-5 portions of tea polysaccharide, 0.6-8 portions of naphthoquine, 0.01-0.15 portion of primaquine, 10-70 portions of sugar, 1-30 portions of starch and 5-40 portions of gum base. The antimalarial green tea chewing gum is made according to the steps of fully mixing the gum base, the sugar and the like, heating the mixture into the paste, cooling the paste below 40 DEG C, adding slowly and stirring the crystalloid artemisinin, the tea polysaccharide, the naphthoquine and the primaquine to the paste, forming a block and cutting the block. Besides, the artemisinin or the derivative thereof, the tea polysaccharide, the naphthoquine and the primaquine can be added to the raw material of the maltose, or the crunchy candy or the granular candy to made into the antimalarial green tea maltose, the antimalarial green tea crunchy candy or the antimalarial green tea granular candy. The antimalarial green tea chewing gum tastes fragrant, sweet and nice, is rich in nutrition, has no toxic side effect and can cool the throat and prevent malaria after being taken for a long time.

The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to gammaherpesvirinae, in particular to the human herpesvirus 8 (HHV8) or the human herpes virus 4 (HHV4), and pharmaceutical compositions containing such compounds.

The invention provides a levoamlodipine maleate eutectic medicine crystallized to triclinic system and a preparation method and application of the levoamlodipine maleate eutectic medicine. The chemical general formula of the eutectic medicine is (C20H26ClN2O5).(C4H3O4).(H2O)n, wherein C20H26ClN2O5 is a molecular formula that primaquine in levoamlodipine (free alkali ) is protonated,C4H3O4 is 2-butenedioic acid (Z) of which one proton is removed, n is greater than or equal to 0 and smaller than 1, the eutectic medicine molecule is crystallized to the triclinic system, P1 chirality space group and crystal cell size are as below: alpha==97.7-97.9 degrees, beta= 92.6-93.0 degrees, and gamma =109.2-109.6 degrees. The eutectic medicine provided by the invention has explicit crystal form, crystalparameters and precise atom space positions, and is different from commercially available levoamlodipine maleate. The preparation method is simple, the granule crystal form is clear, and quality control and large-scale production are easy to perform.

The invention discloses an application of an anti-malarial drug-phosphate primaquine in preparation of drugs for treating leukemia. Through the system screening on multiple drugs approved by the FDA,an anti-malarial drug-phosphate primaquine is found that the phosphate primaquine has significant anti-leukemia effects. At the cellular level, the phosphate primaquine can significantly inhibit the growth of multiple myeloid leukemia cell lines but has no significant growth inhibiting effects on normal human peripheral blood mononuclear cells and neutrophil, and the phosphate primaquine has moreobvious growth inhibiting effects on acute promyelocytic leukemia cells; at the patient level, the phosphate primaquine can inhibit the primary cell colony forming ability of patients with acute myeloid leukemia; and at the animal level, the phosphate primaquine has obvious inhibition effects on all-trans retinoic acid-resistant acute promyelocytic leukemia. The potential clinical transformation and application of the phosphate primaquine in the treating of the leukemia, especially the acute promyelocytic leukemia, can provide important scientific theoretical bases.

The invention belongs to the field of medicine, and particularly relates to an oral pharmaceutical composition for treating myocardial ischemia-reperfusion injury. The oral pharmaceutical compositionfor treating the myocardial ischemia-reperfusion injury is prepared from pharmaceutically acceptable pharmaceutical adjuvants and hyperin, disulfiram, primaquine and rolapitant, wherein the ratios ofthe hyperoside, the disulfiram, the primaquine and the rolapitant are, by weight, 180-300 parts of the hyperoside, 12-20 parts of the disulfiram, 3-9 parts of the primaquine and 2-5parts of the rolapitant. According to the composition, the rolapitant inhibits cardiovascular toxicity of the disulfiram and the primaquine, and eliminates efficacy counteracting phenomenon when the disulfiram and the primaquine are used in combination; the composition of the hyperin, the disulfiram, the primaquine and the rolapidtant has good resistance on the myocardial ischemia-reperfusion injury and safety.

The invention relates to a green tea xylitol drink additive belonging to the drink additive. The green tea xylitol drink additive is characterized by being made from the following raw materials by weight portion: 100 portions of artemisinin, 5-10 portions of tea polysaccharide, 60-600 portions of naphthoquine, 1-15 portions of primaquine and 10-20 portions of xylitol. When the green tea xylitol drink additive is made, the raw materials can be mixed uniformly for later use. The green tea xylitol drink additive can be added to various common drinks to make the refreshing drink, the soda water, the juice, the soymilk, the coffee, the cocoa, the kvass drink, the healthy medical tea drink, the functional electrolyte sports drink and the like. The invention has the advantages of high efficiency, rapid effect, convenient drinking and the like and can be used for treating falciparum malaria and vivax malaria.

The invention discloses a medicine compatibility scheme for treating vivax malaria. The medicine compatibility scheme comprises the following medicine raw materials in a ratio: 17.5mg/kg of artemisinin, 7mg/kg of naphthoquine and 0.9mg/kg of primaquine. The invention further discloses a use method of the medicine compatibility scheme. The use method is that the artemisinin, the naphthoquine and the primaquine of the ratio are taken once per day respectively, and are taken separately for 3 days continuously. The scheme is short in treatment time, that is, can be completed within 3-5 days, and is high in compliance.

This invention relates to novel aminoquinoline derivatives of Formula (I) or Ia, or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an aminoquinoline derivative, such as a derivative of primaquine.